Johnson & Johnson (NYSE:JNJ) has received an average rating of “Hold” from the twenty-two ratings firms that are presently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $145.90.
JNJ has been the topic of several research reports. Citigroup raised their price objective on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. Vetr raised Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price objective on the stock in a research report on Tuesday, October 24th. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. BMO Capital Markets raised their price objective on Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Finally, JPMorgan Chase & Co. lowered Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd.
Johnson & Johnson (NYSE JNJ) traded up $1.92 during trading hours on Wednesday, reaching $133.15. The company’s stock had a trading volume of 7,970,000 shares, compared to its average volume of 9,500,000. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a one year low of $118.05 and a one year high of $148.32. The stock has a market capitalization of $357,710.00, a price-to-earnings ratio of 341.41, a PEG ratio of 2.23 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The company had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same period last year, the company posted $1.58 earnings per share. The firm’s revenue was up 11.5% compared to the same quarter last year. research analysts predict that Johnson & Johnson will post 8.11 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be paid a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. Johnson & Johnson’s payout ratio is currently 861.54%.
A number of hedge funds have recently modified their holdings of the business. Goodman Financial Corp bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $104,000. Harding Loevner LP bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $106,000. Stelac Advisory Services LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $108,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the last quarter. Finally, IHT Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after buying an additional 3,467 shares during the last quarter. Institutional investors own 65.58% of the company’s stock.
WARNING: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/19/johnson-johnson-jnj-given-average-recommendation-of-hold-by-analysts.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.